Denali Therapeutics Inc. Increase (Decrease) in Other Noncurrent Assets
Denali Therapeutics Inc. (DNLI) reported Increase (Decrease) in Other Noncurrent Assets of $304.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$396.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $700.00K, a 25.77% decline year-over-year.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $533.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $1.72M, a 45.76% increase year-over-year.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was -$772.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was -$603.00K.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $0.00.
- Denali Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $304.00K 10-Q · filed 2026-08-06 | $837.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-07 | $1.23M derived: sum of 2 quarters · filed 2026-05-07 | $2.95M derived: sum of 3 quarters · filed 2026-05-07 | -$1.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $533.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.25M derived: sum of 2 quarters · filed 2026-02-26 | -$1.72M derived: sum of 3 quarters · filed 2026-08-06 | -$772.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.25M derived: sum of 2 quarters · filed 2026-08-06 | -$1.30M 10-Q · filed 2025-11-06 | -$3.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.02M 10-Q · filed 2026-08-06 | -$4.80M derived: sum of 3 quarters · filed 2026-08-06 | -$3.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $943.00K 10-Q · filed 2026-05-07 | -$838.00K derived: sum of 2 quarters · filed 2026-05-07 | $340.00K derived: sum of 3 quarters · filed 2026-05-07 | $340.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$603.00K derived: sum of 2 quarters · filed 2026-02-26 | -$603.00K derived: sum of 3 quarters · filed 2026-02-26 | -$603.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.18M derived: sum of 2 quarters · filed 2025-11-06 | $1.18M 10-Q · filed 2025-11-06 | $1.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |